



Medical Industry Week

Princeton, NJ
July 31, 2006

BARRx Medical has completed a US\$27.8 million Series C capital investment programme led by new and existing investors. The company develops treatments for Barrett's oesophagus, a precancerous condition of the lining of the oesophagus caused by gastro-oesophageal reflux disease (GORD).